GATA3 is altered in 14.57% of breast carcinoma patients [3].

GATA3 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

GATA3 is altered in 5.16% of melanoma patients [3].

GATA3 is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [4].

GATA3 is altered in 4.02% of glioblastoma patients [3].

GATA3 is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

GATA3 is altered in 5.68% of bladder carcinoma patients [3].

GATA3 is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

GATA3 is altered in 2.25% of anaplastic astrocytoma patients [3].

GATA3 is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].

GATA3 is altered in 2.11% of non-small cell lung carcinoma patients [3].

GATA3 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

GATA3 is altered in 2.1% of colorectal carcinoma patients [3].

GATA3 is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

GATA3 is altered in 4.02% of malignant solid tumor patients [3].

GATA3 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

GATA3 is altered in 1.71% of sarcoma patients [3].

GATA3 is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

GATA3 is altered in 1.52% of ovarian carcinoma patients [3].

GATA3 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

GATA3 is altered in 1.73% of lymphoma patients [3].

GATA3 is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

GATA3 is altered in 1.08% of head and neck carcinoma patients [3].

GATA3 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

GATA3 is altered in 0.33% of pancreatic carcinoma patients [3].

GATA3 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].